Todd Chappell is currently an Entrepreneur-in-Residence (EIR) at the NIH. As the first EIR at NIH, he will assist the Office of Technology Transfer (OTT) in the evaluation of existing technologies, provide an entrepreneurial perspective to OTT in its evaluation of new licensing proposals from start-up companies, advise OTT on opportunities for new ventures based on NIH/Food & Drug Administration (FDA) technologies, assist with developmental strategies, and mentor scientists to help ensure their research becomes commercially valuable.
From 2009 to early 2012, Todd was Vice President of Operations for Shape Pharmaceuticals, where he oversaw all day-to-day operations involved in the development of a novel HDAC inhibitor for Cutaneous-T-Cell-Lymphoma. Prior to that, he was at CombinatoRx Inc. for eight years and served as Director of New Products. In that role, he led at team of analysts overseeing all early-stage product development and strategy across a range of therapeutic areas including inflammation, infectious disease, dermatology, oncology, and ophthalmology.
Todd directly oversaw the advancement of three programs from assay stage into phase II human clinical studies, and was co-inventor on 10 product patents. He was also responsible for product in-licensing and alliance management for discovery-stage collaborations. Todd holds a B.S. from University of California at Los Angeles and a M.B.A. from Boston University.